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Abstract
BACKGROUND—The National Breast and Cervical Cancer Early Detection Program 
(NBCCEDP) is the largest cancer screening program for low-income women in the United States. 
This study updates previous estimates of the costs of delivering preventive cancer screening 
services in the NBCCEDP.
METHODS—We developed a standardized web-based cost-assessment tool to collect annual 
activity-based cost data on screening for breast and cervical cancer in the NBCCEDP. Data were 
collected from 63 of the 66 programs that received funding from the Centers for Disease Control 
and Prevention during the 2006/2007 fiscal year. We used these data to calculate costs of 
delivering preventive public health services in the program.
RESULTS—We estimated the total cost of all NBCCEDP services to be $296 (standard deviation 
[SD], $123) per woman served (including the estimated value of in-kind donations, which 
constituted approximately 15% of this total estimated cost). The estimated cost of screening and 
diagnostic services was $145 (SD, $38) per women served, which represented 57.7% of the total 
cost excluding the value of in-kind donations. Including the value of in-kind donations, the 
weighted mean cost of screening a woman for breast cancer was $110 with an office visit and $88 
without, the weighted mean cost of a diagnostic procedure was $401, and the weighted mean cost 
per breast cancer detected was $35,480. For cervical cancer, the corresponding cost estimates were 
$61, $21, $415, and $18,995, respectively.
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CONCLUSIONS—These NBCCEDP cost estimates may help policy makers in planning and 
implementing future costs for various potential changes to the program.
Keywords
economic cost; cost analysis; NBCCEDP; breast cancer screening; cervical cancer screening; 
program evaluation
INTRODUCTION
In the United States, screening for breast and cervical cancer is recommended by the U.S. 
Preventive Services Task Force.1 Screening for these cancers has been reported to be 
effective in reducingmorbidity and mortality associated with these cancers through early 
detection and treatment.2,3
Despite evidence showing a modest decrease in incidence and mortality rates associated 
with breast and cervical cancers,4 little progress has been achieved in increasing screening 
rates for these cancers over the last decade.5 In addition, screening rates have been 
substantially lower than the national average among low-income women who are uninsured 
or underinsured,6,7 and these women have been found to be more likely to present with 
advanced-stage cancer than privately insured women.7,8 To reduce disparities in cancer 
mortality rates and provide low-income uninsured women with greater access to cancer 
screening and diagnostic services, in 1990 the US Congress passed the Breast and Cervical 
Cancer Mortality Prevention Act (Public Law 101–354). Detailed descriptions of this law 
and of the National Breast and Cervical Cancer Early Detection Program (NBCCEDP), 
which was formed as a result of it, have been presented previously9 and are also provided 
elsewhere in this Supplement.10 Since 2000, with the implementation of the Breast and 
Cervical Cancer Prevention and Treatment Act, women diagnosed with cancer through the 
NBCCEDP are enrolled in state Medicaid programs to receive treatment.
As the largest organized cancer screening program in the United States, the NBCCEDP is a 
complex system of 68 individual screening programs, each with its own service delivery 
model. Because of this diversity of service delivery models, the operating efficiency of each 
screening program within the NBCCEDP needs to be assessed separately. In 2005, we began 
to systematically collect cost data to comprehensively address economic issues related to the 
NBCCEDP. The NBCCEDP cost estimates presented in this article update and extend 
previously published estimates of the costs of delivering cancer screening services through 
the NBCCEDP during the 2003/2004 fiscal year.9
MATERIALS AND METHODS
Study Population and Definitions
The previous study of NBCCEDP service costs was based on data collected from only 9 
program grant recipients.9 This study is based on data collected from 63 of the 66 grantees 
that received Centers for Disease Control and Prevention (CDC) funding during the 
2006/2007 fiscal year. On the basis of these data, we calculated the following 8 outcomes: 1) 
the mean and median number of women served and the associated total program costs, 2) the 
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cost per woman served with and without in-kind donations, 3) the cost per woman served for 
clinical services, 4) the cost per woman screened for breast and cervical cancer with and 
without office visits, 5) the cost per case of cancer detected, 6) the cost of diagnostic 
procedures performed during an office visit, 7) the cost and percent distribution per woman 
served by each program component, and 8) the relationship between the average cost per 
woman served and the number of women served by the various grant recipients.
In our analyses, “women served” referred to women who received a screening test in the 
program plus women who received a screening test outside the program but were referred to 
the program for a diagnostic procedure; “cost per woman served” referred to the cost of 
screening a woman in the program plus the cost of diagnostic procedure for a woman who 
was screened outside the program but was referred to the program at a diagnostic stage; 
“women screened” referred only to those who received a screening test through the 
NBCCEDP; “screening services” referred to either mammography and clinical breast 
examination for breast cancer screening or a Papanicolaou (Pap) test for cervical cancer 
screening; and “in-kind donations” referred to our estimates of the value of the time of 
volunteers and the value of donated materials for which an NBCCEDP grantee did not have 
to pay. We included the estimated value of these “free” resources in some of our cost 
estimates so that the estimates would reflect the full economic cost of providing cancer 
screening services in the NBCCEDP.
CAT Development and Data Collection
To adequately collect economic costs related to NBCCEDP, we developed a cost assessment 
tool (CAT). The CAT is a standardized web-based instrument designed to collect activity-
based cost data from the NBCCEDP (or other cancer screening programs). Details of the 
development of this tool and an overview of its 11 modules have been presented previously.
11
 Figure 1 summarizes the process used to obtain primary data for this study, which 
included developing the CAT, developing training materials to train grantees on how to use 
the CAT to collect cost data in their respective programs.
We used the CAT to collect cost data for the 2006/2007 fiscal year. Program activities and 
costs related to all funding sources, including the CDC and state and other organizations, 
were collected in the CAT and reported in this study. Data were collected for clinical and 
health promotion activities from each NBCCEDP grantee. “Clinical activities” referred to 
screening, diagnostic follow-up for abnormal results and referral for treatment. “Health 
promotion activities” referred to activities related to program management, patient support/
case management, data management, quality assurance and improvement, partnerships, 
professional development, recruitment, public education, program evaluation, and 
administration. We also collected data on the number of women screened and served by 
NBCCEDP grantees with the use of non-CDC funds as well as with the use of CDC funds.
Data Quality Review and Control
We performed the following steps to ensure the accuracy of data collected with the CAT: 1) 
checked to ensure that all CAT modules were fully and accurately completed; 2) reviewed 
records to ensure that data submitted with the CAT agreed with information grantees 
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provided to CDC in their financial status report; 3) requested that grantees report all funds 
used in the program, including non-CDC funds received from various sources; 4) reviewed 
the submitted data to determine whether grantees reported their actual total expenditures for 
clinical (screening and diagnostic) procedures rather than their rates per procedure; and 5) 
checked to ensure that grantees did not double-report cost data. For grantees with incomplete 
or inaccurate data, we conducted several rounds of follow-up telephone calls to clarify 
inconsistencies, and in some cases we required grantees to resubmit their data. We excluded 
data from 3 grantees that did not meet our data quality criteria, leaving us with data from 63 
grantees for our analysis.
Program Outcome Measures
We obtained the following program outcome measures from the NBCCEDP surveillance 
database and the CDC CAT for non-CDC funded screens: 1) the number of women screened 
for breast cancer and the number screened for cervical cancer with and without CDC funds, 
2) the number of women served in the program with and without CDC funds, and 3) the 
number of breast and cervical cancer cases and precancerous tumors detected. Breast cancer 
cases include invasive cancer and carcinoma in situ (CIS), whereas cervical cancer cases 
include invasive tumors, high-grade cervical intraepithelial neoplasia (CIN; ie, CIN2, CIN3, 
or CIS), and adenocarcinoma in situ.
Data Analysis
The data collected in the CAT and the NBCCEDP surveillance database were analyzed using 
Stata v10 (Stata, College Station, TX). The analysis was conducted from a program 
perspective; therefore, the article only examines direct costs of providing preventive cancer 
screening services and diagnostic procedures to the women participating in the program. 
Because the study was conducted during a 1-year period, we did not discount costs and 
outcome measures.
Calculating Program Costs
Costs were calculated with and without in-kind donations. For all cost calculations, we 
present the arithmetic mean, the weighted mean, and the median. Using the arithmetic mean 
and median, we first calculated the total number of women served per program, the 
cumulative number of women screened with and without CDC funds, the number of women 
who received diagnostic follow-up procedures for abnormal results, and the number of 
cancer cases detected by stage. To express variation across programs, we calculated the 
standard deviation (SD) for reported means and interquartile ranges surrounding the 
medians. These calculations were performed separately for breast and for cervical cancer, 
respectively. Second, we calculated mean and median values for program costs in a similar 
manner. Third, we calculated the weighted mean cost of providing preventive health services 
weighted by the number of women served or screened in each program. We also used 
weighted mean values to estimate cost per woman served by program component as well as 
the corresponding percent distribution by program component. Further, we explored the 
relationship between the calculated average cost per woman served and the number of 
women served.
Ekwueme et al. Page 4
Cancer. Author manuscript; available in PMC 2018 February 22.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
RESULTS
During the 1-year period, the NBCCEDP as a whole served 1.02 million women at a total 
cost of $255.53 million, not counting the estimated value of in-kind donations (Table 1). 
Individual NBCCEDP grantees served an average of 16,135 women (SD, 30,165) at an 
average cost of $4.06 million (SD, $6.41 million). The weighted mean cost per woman 
served excluding the value of in-kind donations was $251.38 (SD, $76.90), of which 
$144.53 (SD, $38.12) was for clinical services. The total weighted mean cost per woman 
served including the $45.05 (SD, $73.89) estimated value of in-kind donations was $296.44 
(SD, $122.55).
Table 2 presents the weighted mean outcomes and costs for breast and cervical cancer 
screening in the program. For breast cancer, the calculated average number of women 
screened by these programs with only CDC funds was 4509 (SD, 4186) and with CDC and 
non-CDC funds was 7850 (SD, 21,520). For cervical cancer, these estimates were 4858 (SD, 
5778) with CDC funds and 6056 (SD, 8220) with and without CDC funds.
Using the weighted mean approach, the cost of screening with an office visit was $109.77 
(SD, $43.80) for breast cancer and $61.38 (SD, $24.82) for cervical cancer (Table 2). 
Without an office visit, the weighted mean cost was $88.44 (SD, $31.23) for breast cancer 
and $20.62 (SD, $18.86) for cervical cancer. The weighted mean cost of a diagnostic 
procedure was $400.68 (SD, $128.39) for breast cancer and $415.16 (SD, $347.13) for 
cervical cancer. The estimated distribution of weighted mean cost and percent distribution 
per woman served by a program component is presented in Figure 2. Screening and 
diagnostic services accounted for the highest cost, of $144.53 (SD, $38.12), which 
represented 57.5% of total program costs per woman served (Fig. 2). Patient support/case 
management was the second highest, with an estimated weighted average cost of $27.90 
(SD, $30.04) per woman served (11.1% of the total costs). Program management was the 
third highest, with an estimated weighted average cost of $25.16 (SD, $18.44) per woman 
served (10.0% of the total costs).
As shown in Table 3, we estimated that 5687 cases of breast cancer were detected during the 
study period by the 63 NBCCEDP grantees whose data we analyzed, an average of 90.3 
cases (SD, 117.2) per grantee, and that the weighted mean cost per cancer case detected was 
$35,480. We estimated that grantees detected an average of 83.2 cases of cervical cancer 
(SD, 111.9) and that the weighted mean cost per cancer case detected was $18,995. As 
shown in Figure 3, data suggest that grantees’ average cost of detecting a case of cancer 
appears to decline as the total number of women they served increases.
DISCUSSION
Excluding the value of in-kind donations, we estimated that the weighted average cost of the 
NBCCEDP per woman served was $251 and that the weighted average cost of clinical 
services per woman served was $145. Including the value of in-kind donations, we estimated 
that the weighted average cost was $296 per woman served. We also estimated that the 
weighted average cost of screening for breast cancer was $110 with an office visit and $88 
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without, that the average cost of the breast cancer diagnostic procedure was $401, and that 
the cost per case of breast cancer detected was $35,480. For cervical cancer, we estimated 
that corresponding costs were $61, $21, $415, and $18,995, respectively. In an era of 
constrained resources for public health programs, these cost estimates calculated directly 
from NBCCEDP can provide useful information for program planning and budget 
allocation. Lack of cost information directly obtained from a program is often a limiting 
factor in using such data to make realistic policy decisions in public health programs. These 
cost estimates provide a baseline against which future NBCCEDP cost estimates can be 
assessed.
As mentioned earlier, these cost estimates update our previous estimates of NBCCEDP costs 
that were based on data from 9 grantees.9 In general, these updated cost estimates were 
slightly higher than those we reported previously. Other previous estimates of the cost of 
mammography screening during an office visit have ranged from $73 to $170 when adjusted 
to 2007 dollars,12–15 and other previous estimates for a Pap test during an office visit have 
ranged from $48 to $118 (in 2007 dollars).16–20 Although cost estimates from different 
studies are difficult to compare because of differences in cost estimation methods, study 
objectives, viewpoint of the analysis, and study settings,21 our estimates of per-person cost 
of services provided by the NBCCEDP are within the range of previous estimates. For 
example, previous estimates of the cost of a diagnostic procedure for breast cancer have 
ranged from $351 to $374,12,14 whereas we estimated that the cost of a procedure in the 
NBCCEDP ranged from $368 to $433. Although numerous studies have assessed the costs 
of breast and cervical cancer screening and diagnosis in the last decade,22,23 few studies 
have assessed the cost of such preventive health services provided through public health 
programs designed for low-income underserved populations.
The NBCCEDP is mandated by law to allocate about 60% of its resources to clinical 
services. In this study, we found that 57.5% of the program resources (excluding the value of 
in-kind donations) are allocated to clinical services, indicating that program administrators 
are, on balance, adhering to this mandate. The law mandates that the remaining 40% of the 
program’s resources be used to support health promotion activities or other nonclinical 
activities essential to the success of clinical services. The provision of resources for health 
promotional activities in this program by policy makers is perhaps in recognition that there 
are other factors that affect the ability of uninsured low-income women to receive cancer 
screening services in addition to financial barriers. Studies have identified these factors to 
include both patient and provider behavior.24–27 For instance, studies have shown that the 
degree to which patients seek cancer screening services is associated with their usual source 
of care, public education, outreach/recruitment, physician recommendation, and 
implementation of interventions to increase professional development of preventive health 
among health providers.28–30 We estimated that the NBCCEDP spends 2.9% of its resources 
on public education, 2.9% on outreach/recruitment activities, and 1.8% on professional 
development. These health promotional activities are used to educate and improve the 
knowledge, skills, and attitudes of the general public about the importance of cancer 
prevention.
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The NBCCEDP attempts to ensure that women who have abnormal screening results receive 
timely diagnosis, affordable care, and treatment. We estimated that for every woman served, 
the program spends $28 (11.1% of its resources) in patient support/case management 
services. These services are considered essential to helping women with limited access to 
health care overcome barriers to receiving services, adhere to screening recommendations, 
receive timely diagnostic recommendations, and make effective use of recommended 
treatment therapies.31–34 Quantifying the amount of program resources that the NBCCEDP 
allocates to different health promotion activities is essential to ensuring that the program is 
accountable for how it uses its resources to encourage women to be screened and to help 
them obtain other recommended preventive health services.
The 2010 Affordable Care Act (ACA) is expected to reduce financial barriers to preventive 
health services such as cancer screening by expanding insurance coverage for these services 
and eliminating copayments and deductibles for millions of low-income Americans. 
Because many of these newly insured people may have limited knowledge of the health care 
system and thus may have difficulty accessing available services,35,36 health care workers 
trained in health promotion activities can play an important role in helping them obtain 
services. In the past 20 years, the NBCCEDP has built a strong infrastructure and gained 
experience in using health promotion activities to help to deliver cancer screening and 
diagnostic services to women with limited access to the health care system. As the nation 
implements the ACA, this infrastructure and experience may be useful in helping newly 
insured people obtain recommended preventive health services. In addition, our estimates of 
the cost of various NBCCEDP health promotion activities (presented in Fig. 2) could be 
used as benchmarks against which current and future expenditures for similar services could 
be compared or as a guide for estimating the financial resources required to provide such 
services for the increased number of women who may have insurance coverage as the result 
of the ACA.
However, extrapolations of our NBCCEDP cost estimates to the much larger population of 
women expected to become eligible to receive preventive health care services under the 
ACA may overestimate the actual cost of such services because the average cost of these 
services may decline as the number of women served increases (as suggested by data 
presented in Fig. 3). However, quantifying the extent to which the per-person cost of service 
provision may decrease as the number of women served increases would require more years 
of program cost data than we had available for this article.
In the past 20 years, NBCCEDP partners have invested a substantial amount of their 
resources to this program. We estimated that the value of in-kind donations to the 
NBCCEDP by its partners amounted to $45 per woman served, or 15% of the estimated 
$296 weighted average cost per woman served in the program. These in-kind donations are a 
clear indication of the strong commitment that NBCCEDP’s various partners have to the 
program and have been instrumental in advancing the program’s ultimate goal of providing 
all US women with access to breast and cervical cancer screening, diagnosis, and treatment 
services. On the other hand, we estimated that NBCCEDP administrators spend 
approximately 1.1% of its resources in developing, maintaining, and sustaining relationships 
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with its partners, which indicates that NBCCEDP administrators understand the importance 
of partner involvement to the success of this program.
Despite our concerted effort to ascertain the true cost of delivering cancer screening services 
in publicly funded cancer screening programs, there are 6 notable limitations to our study. 
First, the cost data presented in this article did not include cost of resources incurred by 
women participating in this program. These resources include transportation cost, child and 
dependent care costs, value of time spent in traveling and receiving preventive cancer 
screening services, and psychosocial costs such as anxiety from false-positive test results. As 
a result, our estimates do not reflect the total societal cost of delivering cancer screening and 
related follow-up services through a publicly funded program. However, this total cost could 
be estimated easily by adding our estimates of program costs to previously published 
estimates of personal costs incurred by program participants, such as the estimate that 
women screened for breast cancer through the NBCCEDP incurred average personal costs of 
$17 (range, $11–$23).37 Such estimates of the total societal cost of specified health care 
services can be used by policy makers for program planning and by researchers attempting 
to estimate societal cost-effectiveness of the NBCCEDP. Second, because we did not have 
another source of information against which to check grantees’ reports of non-CDC funding, 
we were unable to verify the accuracy of these reports; any inaccuracies in these reports 
would obviously have affected the accuracy of our estimates of the total cost of delivering 
cancer screening services in the program. Third, because we analyzed only 1 year of data, 
our estimates do not reflect variations in federal funding levels or in the availability of other 
program resources. To produce multiyear cost estimates that do reflect such variations, we 
are currently collecting multiple years of program cost data. Fourth, our assumption that the 
average costs of office visits for breast and cervical screening were identical may have led us 
to under- or overestimate the costs of screening for these cancers. However, the results of 
previous studies suggest that the impact of this assumption on our cost estimates may have 
been minimal.12–20 Fifth, we did not allocate the estimated value of in-kind donations to 
specific program activities. Finally, because of the short duration of our study period, we had 
to use an intermediate outcome measures (eg, cases of cancer detected)21 rather than a long-
term outcome measure such as life-years gained. However, we are currently conducting 
study designed to estimate life-years gained through the NBCCEDP and have recently 
published some findings from that study.38
These limitations notwithstanding, we believe that the data presented in this article are 
important because they provide primary information on the overall allocation of NBCCEDP 
resources into various activities. This information will be very useful for policy makers in 
determining the amount of resources that may be needed in implementing potential policy, 
systems, and environmental changes in the program. For example, the results reported in this 
article could be used to estimate the amount of resources required to implement a 
population-based organized breast and cervical cancer screening programin the United 
States.
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Figure 1. 
Summary of CAT Development and Activity-Based Cost Data Collection Process.
*The 11 modules in CAT are: 1) Grantee details; (2) Total funding; (3) In-kind contribution, 
(4) Personnel expenditure: (5) Consultant expenditure; (6) Screening expenditure; (7) 
Expenditure for non-screening activities performed by health departments/centers or 
providers; (8) Expenditures associated with contracts, materials, travel and services; (9) 
Administrative expenditures; (10) Resource allocation to breast versus cervical cancer 
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screening for selected activities; and (11) Screening and diagnostic activities supported 
through the use of non-federal funds.
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Figure 2. 
Estimated Distribution of Weighted Mean Costs and Percent Distribution per Woman 
Served, by Program Component. Estimates exclude the value of in-kind contributions, the 
numbers in parentheses are standard deviation, and the numbers in brackets are % 
distribution of cost per woman served by program component.
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Figure 3. 
Average Cost per Woman Served by Number of Women Served in NBCCEDP during 
2006/2007 Fiscal Year.
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TABLE 1
Estimated Outcomes and Costs Among 63a Recipients of CDC Funds for NBCCEDP Activities During 
2006/2007 Fiscal Year
Program Outcomes
  Total number of women served 1,016,492
    Mean number served (SD) 16,135 (30,165)
    Median number served (25th, 75th percentiles) 10,963 (4043, 17,504)
Program Costs With In-Kind Donations Without In-Kind Donations
Total program costs, in millions of $ 301.33 255.53
  Mean cost per program (SD), in millions of $ 4.78 (6.90) 4.06 (6.41)
  Median cost per program (25th, 75th percentiles), in millions of $ 3.21 (1.50, 5.05) 2.46 (1.23, 4.60)
Weighted mean cost per woman served (SD), $ 296.44 (122.55) 251. 38 (76.90)
Weighted Mean cost of clinical services per woman servedb (SD), $ — 144.53 (38.12)
Mean value of in-kind donations per woman servedc (SD), $ 45.05 (73.89) —
Abbreviations: CDC, Centers for Disease Control and Prevention; NBCCEDP, National Breast and Cervical Cancer Early Detection Program; SD, 
standard deviation.
a
Three recipients of CDC funds did not meet data quality criteria for this analysis.
bClinical services include screening and diagnostic services.
c
In-kind donations are defined as those contributions that strictly represent opportunity cost.
Cancer. Author manuscript; available in PMC 2018 February 22.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Ekwueme et al. Page 16
TABLE 2
Weighted Mean Outcomes and Costs for Breast and Cervical Cancer Screening in the Program During 
2006/2007 Fiscal Year
Breast Cancer Screening,
Weighted Mean (SD)
Cervical Cancer Screening,
Weighted Mean (SD)
Program outcome
  Women screened with NBCCEDP funds 4,509 (4,186) 4,858 (5,778)
  Women screened with all funds (ie, CDC + 1 non-CDC funds) 7,850 (21,520) 6,056 (8,220)
  Women receiving diagnostic follow-up visits for abnormal results 1,969 (2,998) 491 (619)
Program cost ($)a
  Cost of screening with an office visit 109.77 (43.80) 61.38 (24.82)
  Cost of a diagnostic procedure 400.68 (128.39) 415.16 (347.13)
  Cost of screening mammography without an office visitb 88.44 (31.23) —
  Cost of Pap smear without an office visitc — 20.62 (18.86)
a
Two programs were dropped from these calculations because of insufficient screening data.
bNo data on the number of mammograms that were performed using non-CDC funds were available, so this calculation includes only the 28 
programs with complete data that did not perform any mammograms using non-CDC funds.
cNo data on the number of Pap tests that were performed using non-CDC funds was available, so this calculation includes only the 33 programs 
with complete data that did not perform any Pap tests using non-CDC funds.
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TABLE 3
Number o f Cancer Cases Detected and Cost per Cancer Detected by the NBCCEDP During 2006/2007 Fiscal 
Year
Breast Cancers Detected Number of Cancers Detected Mean Cancers Detected (SD)
  All breast cancer 5687 90.3 (117.2)
  Carcinoma in situ 1467 23.3 (34.0)
  Invasive cancer 4220 67.0 (89.3)
Cost per Breast Cancer Detected Median by Program (IQR), $ Weighted Mean, $a
  All breast cancer 39,769 (31,538–52,693) 35,480
  Carcinoma in situ 174,398 (104,991–248,704) 137,543
  Invasive cancer 54,896 (42,081–84,549) 47,814
Cervical Cancers Detected Number of Cancers Detected Mean Cancers Detected (SD)
  All cervical cancer 5241 83.2 (111.9)
  High-grade cervical intraepithelial neoplasiab 4981 79.1 (108.3)
  Invasive cancer 260 4.1 (4.5)
Cost per cervical cancer detected Median by Program (IQR), $ Weighted Mean, $a
  All cervical cancer 27,230 (12,377–54,346) 18,995
  High-grade cervical intraepithelial neoplasiab 31,131 (13,040–64,039) 19,986
  Invasive cancer 465,425 (206,028–972,478) 382,892
a
Mean calculated by dividing costs for all programs divided by cancers detected for all programs. Standard deviation not included because some 
programs did not detect any cancers.
b
High-grade cervical intraepithelial neoplasia (CIN) includes CIN2, CIN3, carcinoma in situ, and adenocarcinoma in situ.
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